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Glutaric acidemia type 1 is an inherited metabolic disorder which can cause
macrocephaly, muscular rigidity, spastic paralysis and other progressive move-
ment disorders in humans. The defects in glutaryl-CoA dehydrogenase (GCDH)
associated with this disease are thought to increase holoenzyme instability and
reduce cofactor binding. Here, the ﬁrst structural analysis of a GCDH enzyme
in the absence of the cofactor ﬂavin adenine dinucleotide (FAD) is reported.
The apo structure of GCDH from Burkholderia pseudomallei reveals a loss of
secondary structure and increased disorder in the FAD-binding pocket relative
to the ternary complex of the highly homologous human GCDH. After
conducting a fragment-based screen, four small molecules were identiﬁed which
bind to GCDH from B. pseudomallei. Complex structures were determined for
these fragments, which cause backbone and side-chain perturbations to key
active-site residues. Structural insights from this investigation highlight
differences from apo GCDH and the utility of small-molecular fragments as
chemical probes for capturing alternative conformational states of preformed
protein crystals.
1. Introduction
Glutaryl-CoA dehydrogenase (GCDH) is an acyl-CoA dehydro-
genase (ACDH) which catalyzes an intermediate step in the meta-
bolic breakdown of lysine and tryptophan (Gomes et al., 1981; Kim &
Miura, 2004; Lenich & Goodman, 1986; Goodman et al., 1995).
Unlike other ﬂavoproteins within this family, GCDH (EC 1.3.99.7)
performs  , -dehydrogenation as well as decarboxylation of its sub-
strate glutaryl-CoA to yield the product crotonyl-CoA (Dwyer et al.,
2000). Transfer of electrons from the glutaryl-CoA precursor to the
electron-transfer ﬂavoprotein is mediated by the cofactor ﬂavin
adenine dinucleotide (FAD) in both prokaryotic and eukaryotic
electron-transport chains (Tsai & Saier, 1995). Defects in GCDH are
reponsible for glutaric acidemia type 1 (GA1), an inherited metabolic
disorder which prevents the complete breakdown of lysine and
tryptophan (Strauss et al., 2003; Strauss & Morton, 2003; Goodman
et al., 1998). This disease manifests as macrocephaly and bleeding
abnormalities in newborns, as well as muscular rigidity, spastic
paralysis and other progressive movement disorders in older indivi-
duals (Strauss et al., 2003; Hedlund et al., 2006). Treatments for this
disease include intravenous delivery of carnitine, which is depleted as
a secondary effect of GA1, and a restricted-protein diet to limit lysine
and tryptophan buildup in the circulatory system. The statistical
chance of inheriting GA1 worldwide is 1:100 000, but is as high as
1:300 in Old Order Amish communities in Pennsylvania and other
ethnic societies (Morton et al., 1991). To date, over 80 mutations,
including missense, nonsense and intronic variations, have been
associated with GA1 in patients (Keyser et al., 2008; Westover et al.,
2003; Goodman et al., 1998). However, controversy persists con-
cerning attempts to connect phenotype to speciﬁc genotypic markers
of the disease, as patients symptomatic for GA1 sometimes do not
present with GCDH deﬁciency (Westover et al., 2003; Christensen et
al., 2004; Garcia et al., 2008).
Sequence differences between mammalian and bacterial GCDHs
can be large for speciﬁc anaerobes, in which GCDH plays a crucial
role in benzoyl-CoA degradation. Preliminary evidence suggests that
certain obligate anaerobes possess two distinct enzymes whichseparately perform the dehydrogenation and decarboxylation steps
(Wischgoll et al., 2009, 2010). However, a detailed phylogenetic
analysis of the ACDH superfamily shows certain bacterial GCDH
genes nesting closer to eukaryotic sequences than to genes from other
bacteria, suggesting a lateral gene transfer from eukaryotes to
proteobacteria (Swigonova ´ et al., 2009). We performed a similar
analysis to include the protein sequence of GCDH from Burkholderia
pseudomallei and found that this enzyme was situated within the
eukaryotic gene-transfer group (Fig. 1). Together, the sequence
correlation and high structural homology (see below) suggest that
structural insights gained for GCDH from B. pseudomallei will have
consequences related to the human enzyme.
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Figure 1
A bootstrapped nearest-neighbour-joining phylogenetic tree of glutaryl-CoA dehydrogenases from a selection of eukaryotic (black), archaeal (red) and aerobic (cyan)
bacterial species, plus one prokaryotic obligate anaerobe (green). A subtree for B. pseudomallei (underlined) and other related prokaryotes is well supported within
eukaryota and is suggestive of lateral gene transfer. The alignment was performed using ClustalX2 v.2.0 (Chenna et al., 2003).At the time of writing, seven structures of GCDH are available in
the Protein Data Bank (PDB) from the human, Thermus thermo-
philus and Desulfococcus multivorans gene products, all of which
contain the bound cofactor FAD (Fu et al., 2004; Rao et al., 2007;
Thorpe & Kim, 1995; Wischgoll et al., 2010). Here, we report the ﬁrst
structures of GCDH from B. pseudomallei (BpGCDH), including the
ﬁrst apo structure of any GCDH characterized in the absence of
FAD. The results of this investigation allow a detailed comparison
between human and bacterial GCDH and determination of the
structural consequences associated with the apo structure. Among
these differences, a tyrosine side chain adjacent to the catalytic
glutamate residue in apo BpGCDH is rotated nearly 180  from its
position in the human ternary complex and appears to block the
ﬂavin-binding site. By soaking our Fragments of Life small-molecule
library (Davies et al., 2009; Begley et al., 2011) into crystals of apo
BpGCDH, complexes were formed whose crystal structures showed
backbone hydrogen-bond interactions replaced by the catalytic
glutamate side chain. These structures shed light on the structural
ﬂexibility available to GCDH and demonstrated the use of small-
molecular fragments as chemical probes for capturing alternative
conformational states.
2. Experimental methods
2.1. Protein expression and purification
Full-length glutaryl-CoA dehydrogenase (GCDH; UniProt
Q3JP94) was obtained from puriﬁed B. pseudomallei strain 1710b
genomic DNA, which was kindly provided by Rajinder Kaul from the
University of Washington. The gene was ampliﬁed using the following
primer sequences: FWD primer 50-GGGTCCTGGTTCGATGGCT-
GCCGCAACCTTCCAC-30 and REV primer 50-CTTGTTCGTGC-
TGTTTATTAGAAGAACGCCTGAATCCCCGTC-30 (Invitrogen).
The PCR conditions were 35.2 ml deionized H2O (Sigma, catalog No.
W3513), 5 ml Expand High Fidelity Buffer (10 )w i t h1 5m M MgCl2
(Roche), 0.4 ml2 5m M dNTPs (Qiagen, catalog No. 201912), 0.4 ml
Expand High Fidelity Enzyme Mix (Roche, catalog No.
11732641001), 4 ml FWD primer, 4 ml REV primer and 1 ml (10 ng)
B. pseudomallei 1710b genomic DNA. Thermal cycling conditions
were 367 K for 2 min followed by 30 cycles of 367 K (30 s), 333 K
(1 min) and 345 K (4 min 30 s) and a ﬁnal extension of 345 K for
10 min using a Bio-Rad MJ Research PTC-200 thermal cycler. PCR
amplicons were run on agarose gel to verify the expected size of the
ampliﬁed gene, which was followed by excision and extraction from
the gel using a QiaQuick kit (Qiagen, catalog No. 28181).
The puriﬁed PCR product was cloned into the expression vector
AVA0421 with a cleavable 6 His fusion tag followed by the human
rhinovirus 3C protease-cleavage sequence (MAHHHHHHMGTL-
EAQTQGPGS-ORF for the entire tag sequence N-terminal to the
target gene) by ligation-independent cloning (LIC; Aslanidis & de
Jong, 1990). Brieﬂy, puriﬁed PCR product was treated with T4
polymerase in the presence of the single nucleotide dATP, creating
overhangs, and then annealed with compatible, linearized and T4-
treated AVA0421 vector (Mehlin et al., 2006). Annealed vector and
insert were transformed into NovaBlue competent cells (Novagen,
catalog No. 71011-4) and plated on LB agar (BD Difco LB Agar
Miller-BD, catalog No. 244520) with 50 mgm l
 1 each of ampicillin
(Anatrace, catalog No. A1000) and carbenicillin (Duchefa Bio-
chemie, catalog No. C0109.0025) to select for cells carrying the
expression plasmid. The presence of the insert was veriﬁed by colony
PCR under the above conditions, but the colony itself was resus-
pended in water and used as template instead of puriﬁed DNA.
Plasmid DNA was puriﬁed (QIAprep Turbo Miniprep kit; Qiagen,
catalog No. 27191) from 1 ml overnight cultures and then trans-
formed into the expression host Escherichia coli BL21 Star (DE3)
(Invitrogen, catalog No. C6010-03).
2 l cultures of GCDH were grown in a LEX bioreactor (Harbinger)
at 293 K in auto-induction medium (Studier, 2005). After 72 h of
growth, the culture was pelleted in a Sorvall RC 12BP ﬁtted with an
H-12000 rotor by spinning for 20 min at 4300 rev min
 1, after which
the cell paste was harvested and ﬂash-frozen in liquid nitrogen.
Unless otherwise noted, the protein was puriﬁed at room tempera-
ture. To prepare protein samples, the cell paste was solubilized on ice
in lysis buffer (25 mM HEPES, 500 mM NaCl, 5% glycerol, 30 mM
imidazole, 0.5% CHAPS, 10 mM MgCl2,1m M TCEP, 250 ng ml
 1
AEBSF pH 7.0) with 0.01 g lysozyme. The cell paste was sonicated on
ice for 30 min (100 W; cycles of 15 spulse-on and 15 s pulse-off; Virtis,
catalog No. 408912). After sonication, samples were treated with
Benzonase (500 U total) and then centrifuged for 1 h at 277 K
(14 000 rev min
 1 in a Sorvall SLA-1500 rotor) to clarify cell debris.
The protein was puriﬁed by immobilized metal ion-afﬁnity chroma-
tography on pre-equilibrated (25 mM HEPES pH 7.0, 500 mM NaCl,
5% glycerol, 30 mM imidazole, 1 mM TCEP and 0.025% azide) 5 ml
Ni Sepharose columns (HisTrap FF; GE Healthcare, catalog No.
17-5255-01) using an A ¨TKAexplorer. After thorough washing, bound
protein was eluted from the nickel column by the addition of elution
buffer (25 mM HEPES pH 7.0, 500 mM NaCl, 5% glycerol, 1 mM
TCEP, 250 mM imidazole and 0.025% azide). Fractions from nickel-
afﬁnity chromatography were analyzed for protein content by SDS–
PAGE and pooled. His-MBP-3C protease was added to the target
protein at a 1:50(w:w) ratio in order to remove the N-terminal 6 His
tag. The protease was incubated overnight at 277 K in 3C buffer
(20 mM HEPES, 200 mM NaCl, 5% glycerol, 1 mM TCEP pH 7.5)
and the cleaved protein was passed over Ni resin beads (Ni Sepharose
6 Fast Flow; GE Healthcare, catalog No. 17-5318-02) to remove
noncleaved protein, the cleaved 6 His tag, His-tagged 3C protease
and any contaminants which bind to nickel. After cleavage, the
construct generated retains a GPGS- sequence, followed by the ﬁrst
N-terminal methionine of GCDH. Clariﬁed cleaved protein was then
further puriﬁed by size-exclusion chromatography (SEC; HiLoad 26/
60 Superdex 75; GE Healthcare, catalog No. 17-1071-01) using an
A ¨TKAprime in SEC buffer (25 mM Tris pH 8.0, 200 mM NaCl, 1%
glycerol and 1 mM TCEP). SEC fractions were analyzed by SDS–
PAGE, showing a single band at the expected elution volume. The
highest intensity SEC fractions were pooled and concentrated
to approximately 26 mg ml
 1 using Amicon Ultra-15 concentrators
with a molecular-weight cutoff of 3000 Da (Fisher, catalog No.
UFC901096). Protein samples were aliquoted in 100 ml volumes,
ﬂash-frozen in liquid nitrogen and stored at 193 K.
2.2. Crystallization and fragment screening
Sitting-drop vapor-diffusion crystallization trials were set up at
289 K using the JCSG+, PACT and Cryo Full sparse-matrix screens
from Emerald BioSystems and the Crystal Screen HT sparse-matrix
screen from Hampton Research. Protein solution (0.4 ml) was mixed
with reservoir solution (0.4 ml) and equilibrated against 100 ml
reservoir solution using 96-well Compact Jr plates from Emerald
BioSystems. Crystals grew in several conditions, but those used in
X-ray data collection and structure determination were obtained
using a reservoir solution consisting of 20% PEG 3000, 100 mM
HEPES, 200 mM NaCl pH 7.5. Crystals of apo BpGCDH were
cryoprotected using 25%(v/v) ethylene glycol in the reservoir solu-
tion prior to freezing in liquid nitrogen and data collection.
structural communications
1062 Begley et al.   Glutaryl-CoA dehydrogenase Acta Cryst. (2011). F67, 1060–1069Fragment screening was performed on preformed GCDH crystals
with a metabolome-derived small-molecule library of 1440 fragments
following previously published methods (Davies et al., 2009; Begley et
al., 2011). Brieﬂy, pools of up to eight fragment ligands were prepared
from concentrated methanol stock solutions with each ligand at
6.25 mM in the mixture. One 1.0 ml drop of each methanol pool was
then added to an empty sitting-drop well and the methanol was
allowed to completely evaporate, leaving behind a dry ﬁlm of frag-
ment compounds. The fragments were resuspended in 1.0 ml reservoir
solution and 2–3 crystals of apo BpGCDH were transferred to each
well, with 20 ml reservoir solution being added to each reservoir prior
to sealing. After 7–14 d of soaking at 289 K, fragment-soaked crystals
were dipped into cryoprotectant solution prior to freezing in liquid
nitrogen and data collection. The cryoprotectant consisted of 0.25 ml
ethylene glycol and 0.75 ml reservoir solution, with a fresh prepara-
tion of 6.25 mM resuspended fragments present. All fragments found
to bind crystals of BpGCDH in mixtures were followed up by indi-
vidual fragment soaks at 10–25 mM followed by cryoprotection and
X-ray data collection to conﬁrm the identity of each small molecule.
2.3. Data collection and structure determination
Preliminary data sets were collected in-house using a Rigaku
SuperBright FR-E+ X-ray generator with Osmic VariMax HF optics
and a Saturn 944+ CCD detector. The ﬁnal data sets for the individual
BpGCDH structures discussed in this work were collected on the
APS 21-ID-D, APS 23-ID-D and ALS 5.0.3 synchotron beamlines
and were reduced with HKL-2000 (Otwinowski & Minor, 1997). The
apo structure was solved by molecular replacement using Phaser
from the CCP4 suite of programs (Winn et al., 2011) with molecule A
from the structure of human GCDH (PDB entry 1siq; Fu et al., 2004)
as the search model. All crystal structures were initially rebuilt with
ARP/wARP (Langer et al., 2008), followed by numerous reiterative
rounds of reﬁnement in REFMAC (Murshudov et al., 2011) and
manual model building using the Crystallographic Object-Oriented
Toolkit (Coot; Emsley & Cowtan, 2004). For direct fragment-mixture
screening by crystallography, unmodeled electron density with
(Fo   Fc)>2 . 5   and (2Fo   Fc)>1 . 0   was ﬁrst veriﬁed against the
model protein structure using Coot. Unmodeled electron density that
was likely to be protein or buffer components was ignored and the
remaining density regions were examined for shape complementarity
with individual fragments in a given mixture. Individual fragment-
soaking experiments were then conducted and new data sets were
collected to conﬁrm the identity of each bound small-molecule
fragment. Fragment-bound structures were solved by molecular
replacement from the apo BpGCDH structure, using CCP4t o
generate small-molecule structures. Each structure was evaluated
using MolProbity (Chen et al., 2010) and manually checked by
structural communications
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Table 2
Reﬁnement statistics.
Values in parentheses are for the highest of 20 resolution shells.
PDB code 3eom 3eon 3gnc 3d6b 3gqt
Resolution range (A ˚ ) 30.000–2.398 (2.460–2.398) 46.630–2.550 (2.616–2.550) 46.68–2.15 (2.21–2.15) 47.190–2.210 (2.27–2.21) 50.0–1.99 (2.04–1.99)
No. of reﬂections above   cutoff in ﬁnal cycle 60090 49412 81910 76240 103473
Rcryst 0.213 0.191 0.209 0.212 0.202
No. of reﬂections for Rfree† 3035 (212) 2476 (179) 4105 (291) 3826 (222) 5175 (377)
Final Rfree† 0.264 (0.369) 0.266 (0.330) 0.255 (0.332) 0.261 (0.356) 0.238 (0.295)
Overall average B factor (A ˚ 2) 60.4 42.6 37.4 36.5 38.3
Average ligand B factor (A ˚ 2) — 74.2 48.51 58.28 43.64
No. of protein atoms 11741 11681 11546 11436 11525
No. of ligand atoms — 10 114 9 42
No. of solvent atoms 167 206 210 500 286
Total No. of atoms 11908 11897 11870 11945 11853
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using the 5% of the reﬂections that were omitted from the reﬁnement).
Table 1
Data-collection statistics.
Values in parentheses are for the highest of 20 resolution shells.
PDB code 3eom 3eon 3gnc 3d6b 3gqt
Space group P212121 P212121 P212121 P212121 P212121
Matthews coefﬁcient VM
(A ˚ 3 Da
 1)
2.20 2.15 2.16 2.21 2.16
Unit-cell parameters (A ˚ ) a = 98.12, b = 106.77,
c = 145.43
a = 97.41, b = 106.17,
c = 144.19
a = 98.24, b = 106.10,
c = 144.24
a = 98.50, b = 107.47,
c = 144.31
a = 97.42, b = 106.37,
c = 144.77
Diffraction source APS beamline 21-ID-D APS beamline 21-ID-D ALS beamline 5.0.3 APS beamline 23-ID-D ALS beamline 5.0.3
Diffraction protocol Single wavelength Single wavelength Single wavelength Single wavelength Single wavelength
Monochromator Kohzu double crystal Kohzu double crystal Asymmetric cut single
crystal Si(220)
Cryocooled crystal Asymmetric cut single
crystal Si(220)
Wavelength (A ˚ ) 1.00 1.00 0.97 1.00 0.97
Detector MAR Mosaic 300 mm CCD MAR Mosaic 300 mm CCD ADSC Quantum 315 CCD MAR Mosaic 300 mm CCD ADSC Quantum 315 CCD
Temperature (K) 100 100 100 100 100
Resolution range (A ˚ ) 50.00–2.40 (2.49–2.40) 50.00–2.40 (2.49–2.40) 50.00–2.15 (2.19–2.15) 50.00–2.20 (2.28–2.20) 50.0–1.99 (2.06–1.99)
Total unique reﬂections 60203 59702 81993 76333 103621
Completeness (%) 99.5 (98.2) 98.7 (98.5) 99.6 (98.5) 99.6 (97.7) 100.0 (100.0)
Multiplicity 7.0 (6.5) 7.2 (5.9) 7.0 (6.8) 7.0 (5.7) 7.2 (6.1)
Mean I/ (I) 23.7 (2.4) 17.0 (2.2) 10.8 (2.1) 8.5 (2.3) 10.1 (2.0)
Rmerge† 0.084 (0.658) 0.118 (0.894) 0.072 (0.593) 0.105 (0.748) 0.073 (0.686)
Phasing method Molecular replacement Molecular replacement Molecular replacement Molecular replacement Molecular replacement
Starting model data set 1siq 3eom 3d6b 3eom 3d6b
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.internal peer review prior to structure validation and deposition in
the Protein Data Bank (Berman et al., 2000, 2003). Data-collection
(Table 1) and reﬁnement (Table 2) statistics are listed for apo
BpGCDH and four fragment-bound complexes.
3. Results and discussion
3.1. The apo structure of GCDH from B. pseudomallei
Like other ACDHs, GCDH from B. pseudomallei (BpGCDH)
exists as a homotetramer with tetrahedral symmetry and possesses an
overall fold similar to that of the human enzyme (Fu et al., 2004).
Each protomer of BpGCDH consists of an N-terminal solvent-facing
region of ﬁve  -helices followed by a ﬂattened seven-stranded
pseudo- -barrel and a C-terminal  -helix core (Fig. 2). The C-term-
inal domain comprises much of the tetrameric binding surface and
forms parts of both the FAD and the glutaryl-CoA binding pockets.
Residues that are critical for enzymatic activity in the human enzyme
are conserved in the bacterial sequence, including the catalytic
glutamate Glu374 (Glu370 in human) which abstracts an   proton
from the substrate (Fu et al., 2004; Rao et al., 2007). At the time of
writing, all GCDH structures in the PDB possess FAD bound in the
cofactor-binding pocket (PDB entries 1siq, 1sir, 2r0m, 2r0n, 2eba,
3mpi and 3mpj; Fu et al., 2004; Rao et al., 2007; T. S. Kumarevel, P.
Karthe, S. Kuramitsu & S. Yokoyama, unpublished work; Wischgoll et
al., 2010). None of these structures report FAD as a crystallization
additive, despite its presence in the ﬁnal structure. This suggests that
the cofactor is usually carried through puriﬁcation, with sufﬁcient
binding afﬁnity for GCDH to remain bound through multiple puri-
ﬁcation steps (Fu et al., 2004; Rao et al., 2007; Thorpe & Kim, 1995;
Wischgoll et al., 2010). In our study, overexpression of BpGCDH
in E. coli and standard protein-puriﬁcation methods did not yield
crystals with FAD bound (see Methods). The absence of electron
density in the cofactor-binding pocket of multiple BpGCDH data
sets, together with key differences from the human ternary complex,
conﬁrm this result. Analysis of the apo bacterial structure (BpGCDH;
PDB entry 3eom) overlaid with the human ternary complex with
FAD and the substrate mimic S-4-nitrobutyryl-CoA (NBC)
(hGCDH; PDB entry 1sir; Fu et al., 2004) reveal structural conse-
quences of this loss of cofactor. In all four protomers of BpGCDH,
electron density was too poor to model from Thr139 to Asp145. This
loop extends from the pseudo- -barrel region into part of the FAD-
binding site, as seen in Thr136–Asp143 of hGCDH (Fig. 3), acting as a
wall to separate the diphosphate of FAD from the alkyl pantothenate
moiety of glutaryl-CoA (Fu et al., 2004; Rao et al., 2007). In a different
region of the human complex, a short  -helical turn comprises part of
the ﬂavin-binding site and the adjacent protomer interface. This
helical character is lost in two of the four protomers of the apo
BpGCDH structure (Fig. 3), further suggesting that FAD binding
structural communications
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Figure 3
(a) A single protomer of apo BpGCDH (green; PDB entry 3eom) overlaid with the
human ternary complex (gray; PDB entry 1sir; Fu et al., 2004) containing FAD
(black) and the substrate mimic NBC (white). Regions of structural difference
between the two protomers (bacterial, magenta; human, yellow and cyan) are
largely contained within terminal loop regions. (b) The interface between two
protomers of bacterial (green/orange) and human (dark gray/white) GCDH. The
human ternary complex reveals an  -helical contact region between protomers
(yellow) which is a less ordered loop in BpGCDH (magenta). Density modeled on
the opposite protomer in the human complex (cyan) is too disordered to model in
the bacterial apo crystal data set.
Figure 2
Tetrameric glutaryl-CoA dehydrogenase from B. pseudomallei (BpGCDH; PDB
entry 3eom) overlaid with one protomer of human glutaryl-CoA dehydrogenase
(PDB entry 1sir; Fu et al., 2004). The BpGCDH tetramer (green, cyan, magenta and
yellow) is in the apo state, while the hGCDH protomer (gray) is in a ternary
complex with the cofactor FAD (black) and the substrate mimic S-4-nitrobutyryl-
CoA (NBC; white).helps to maintain secondary structure at crucial protomer protein
binding surfaces.
Root-mean-square deviations (r.m.s.d.s) for main-chain atomic
coordinates between the human ternary complex and the bacterial
apo structure are small (<0.5 A ˚ ) near the catalytic glutamate residue
(Fig.4). Side-chain rotamers between the two enzymes also tend to be
well conserved along this sequence, with the exception of Tyr373.
During catalysis, this tyrosine hydrogen bonds to Arg97 (Arg94 in
human) and interacts with the terminal carboxylate of the glutaryl-
CoA substrate, which is enzymatically released as CO2 (Fu et al.,
2004). This tyrosine is also important for proper positioning of the
substrate, creating a hydrophobic lining for the bottom of the active
site (Fu et al., 2004; Rao et al., 2007; Thorpe & Kim, 1995; Wischgoll et
al., 2010). In our apo BpGCDH structure this tyrosine is ﬂipped
nearly 180  from its position in the human complex, with a distance
of approximately 9.2 A ˚ between aromatic hydroxyls (Fig. 5). In the
absence of substrate and cofactor Tyr373 no longer hydrogen bonds
to Arg97. Instead, the apo structure reveals Glu370 participating
in a water-mediated contact to Arg97, with the catalytic glutamate
carboxyl having moved 3.8 A ˚ away from where it sits in the human
enzyme. In this new location it partially occupies the substrate-
binding site, but at a distance and orientation which prevent efﬁcient
structural communications
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Figure 4
Root-mean-square deviations from the apo structure of B. pseudomallei GCDH for (a) main-chain and (b) side-chain atomic coordinates of human GCDH as well as
fragment-bound structures of BpGCDH near the catalytic activesite.(a) The backbone residues of the human GCDH–FAD–NBC ternary complex are structurally similar to
those of apo BpGCDH. Binding small molecules causes backbone conformational changes which deviate from the apo BpGCDH structure. (b) The side-chain deviations
between the apo bacterial structure and the human ternary complex tend to be smaller than those observed between apo and fragment-bound structures of BpGCDH. PDB
codes are listed in the legend and the structures of all four GCDH-binding fragments are shown at the top. The alignment was performed using the SSM superposition
function from the CCP4 program suite (Krissinel & Henrick, 2004; Winn et al., 2011).hydrogen-bonding to the Arg97-bound water (Fig. 5). Thus, the
tyrosine side chain of apo BpGCDH must rotate by 180  and displace
a conserved water molecule in order to attain a conformation suitable
for FAD binding.
3.2. Fragment-bound complexes of BpGCDH
With a robust reproducible apo crystal system in hand, we
conducted a fragment-based screen of BpGCDH to search for novel
small molecules with afﬁnity for either the substrate- or cofactor-
binding sites. Additional structures of BpGCDH resulting from this
effort were obtained by soaking apo BpGCDH crystals in drops
containing our Fragments of Life (FOL) ligand collection (Davies et
al., 2009; Begley et al., 2011) prior to data collection. Approximately
10% of all BpGCDH crystals completely dissolved when added to
soaking drops containing fragment mixtures and over half did not
diffract after soaking. Thus, a wide variety of small molecules appear
to destabilize crystals of apo BpGCDH when present in the drop.
After soaking BpGCDH crystals in 181 different mixtures, 60 unique
data sets were successfully collected from primary screening, repre-
senting approximately 480 tested small molecules. Follow-up soaking
experiments after primary screening conﬁrmed the identiﬁcation of
four unique fragment binders for BpGCDH, which are described
below. Of these, one structure (PDB entry 3gnc) with FOL6421 [1-
(1-methylethyl)-1H-benzimidazole-2-sulfonate] bound also contains
well resolved molecules of HEPES [4-(2-hydroxyethyl)-1-piperazine-
ethanesulfonic acid] located in solvent-accessible cavities of the
tetrahedral interface. Despite the presence of 100 mM HEPES in
the crystallization condition and the soaking drop, neither the apo
structure nor the other fragment-bound crystals of BpGCDH showed
electron density for this buffer component that was sufﬁcient for
modeling. This appears to be a pH-dependent effect as FOL6421 is
the only acidic fragment in the set, it is present at high concentration
during the soak and no structural differences are found to account for
this case.
In performing its native function, GCDH binds two metabolites:
the glutaryl coenzyme A substrate and the cofactor FAD. Data for
480 unique small-molecule fragments showed none that occupy the
regions that bind the phosphoadenylates of either the substrate or
the cofactor of BpGCDH. Although adenine, ADP and other purine
structural communications
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Figure 5
(a) Active site of the human ternary complex (PDB entry 1sir; Fu et al., 2004), showing key interactions between FAD (black), the substrate mimic NBC (white) and key
protein residues (gray). (b) Overlay of the active site in (a) with that of apo GCDH from B. pseudomallei (green; PDB entry 3eom), highlighting the nearly 180  rotation of
Tyr373 in the bacterial structure relative to Tyr369 in human GCDH. (c) Overlay of the active site in (a) with that of the bacterial structure bound to two molecules of
FOL680 (orange;PDB entry 3gqt). Backbone devations occur downstream of the catalytic glutamate, while Tyr373 is rotated back to the position seen in the human complex.
(d) Overlay of the apo and FOL680-bound bacterial GCDH active sites.analogs were contained within pools for which data were collected,
electron density for these molecules was not observed after soaking
and X-ray diffraction. All fragments identiﬁed by screening
which bind BpGCDH (Fig. 4) occupy the pockets that bind the
glutaryl and ﬂavin moieties ofthe substrate and cofactor, respectively.
Although much smaller than either the substrate or the cofactor,
these fragments appear to stabilize crystals of BpGCDH, with a
reduction in the overall B factor averaging 20 A ˚ 2 relative to the apo
structure, regardless of which fragment binds (Table 2). Crystals
containing FOL239 (3,5-diﬂuorobenzyl alcohol; PDB entry 3eon) and
FOL544 (methyl thiophene-2-carboxylate; PDB entry 3d6b) each
possess one fragment bound in one active site per BpGCDH
tetramer. FOL6421 (PDB entry 3gnc) was observed bound in all four
active sites of tetrameric BpGCDH. Finally, a single molecule
of FOL680 [(1,4-dimethyl-1,2,3,4-tetrahydroquinoxalin-6-yl)methyl-
amine; PDB entry 3gqt] bound to one active site of BpGCDH
(Fig. 6), while two molecules of FOL680 were observed within the
active site of the tetrahedrally opposite protomer (Fig. 5), resulting in
a total of three ligands bound per tetramer.
In three of the four ligand-bound complexes fragment molecules
occupy the binding site for the terminal glutamate of the glutaryl-
coenzyme A substrate (Figs. 5 and 6). The crystallographic water
coordinated to the Arg97 side chain in the apo structure of BpGCDH
remains in place when FOL544 is bound, but is displaced by FOL239
and FOL6421. In all three of these cases the Tyr373 side chain is
rotated approximately 90  from its position in both theapo BpGCDH
structure and the human ternary complex (Figs. 5 and 6). This new
position appears to facilitate ligand binding by providing a parallel
aromatic surface that aligns with the heteroaromatic rings of all three
fragments. For FOL544 (PDB entry 3d6b) and FOL239 (PDB entry
3eon) this position also allows hydrogen bonding between the
hydroxyl of Tyr373 and the carbonyl of Trp169, with oxygen–oxygen
distances of 3.1–3.2 A ˚ .
The Tyr373 side chain of the fourth fragment-bound complex
containing FOL680 greatly differs from the other three, resulting in a
position nearer to that seen in the human ternary complex (Fig. 5).
This is an approximately 180  rotation from the apo state and a 90 
rotation from the other fragment-bound structures. The same rota-
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Figure 6
Active sites of apo BpGCDH (green; PDB entry 3eom) overlaid with complexes containing bound fragments, represented as lines. (a) FOL239 (yellow; PDB entry 3eon) was
observed in one active site per tetramer. (b) FOL544 (cyan; PDB entry 3d6b) was also observed in one active site per tetramer. (c) FOL6421 (magenta; PDB entry 3gnc) was
observed in all four active sites of tetrameric BpGCDH. (d) One molecule of FOL680 (orange; PDB entry 3gqt) was observed in one active site as shown, while two were
observed in another active site (Fig. 5), resulting in three molecules of FOL680 per BpGCDH tetramer.tional change of Tyr373 occurs whether one or two molecules of
FOL680 are present in a single active site. When one molecule is
present, FOL680 occupies the binding site for the ﬂavin ring of the
FAD cofactor (PDB entry 3gqt). When two molecules are present the
ﬁrst occupies the same position and orientation in the ﬂavin site,
while the second binds in the substrate site closer to the pantetheine
sulfur than to the carboxy-terminus of the substrate site. Like the
other fragment binders, this second molecule of FOL680 is parallel to
the phenyl ring of Tyr373 (Fig. 6). Insufﬁcient density was available to
capture the Tyr373 rotamer in the two remaining BpGCDH proto-
mers of 3gqt, suggesting a low energy barrier for this side chain. Thus,
the rotational mobility of Tyr373 in the absence of FAD allows the
formation of at least two distinct pockets capable of binding small-
molecule ligands in preformed crystals of apo BpGCDH.
Despite several structural differences between the apo bacterial
structure and that of FAD-bound human GCDH, apo BpGCDH
shows little backbone variation from the human ternary complex
near the catalytic glutamate (Fig. 4). However, a conserved backbone
deviation is observed between the structure of apo BpGCDH and
those of all four fragment-bound complexes in this same region. In all
four fragment-bound structures Thr376 and His377 are ﬂipped out
of the  -helix observed in the apo state, partially occupying the
binding pocket for the adenosine moiety of FAD (Fig. 6). This
perturbation results in a new orientation of the catalytic YEG motif.
In the apo structure of BpGCDH as well as the human ternary
complex, a network of hydrogen bonds occur between the backbone
carbonyls of Tyr373, Glu374 and Gly375 and side-chain atoms of
Arg254, Lys331 and His380 (Tyr370, Glu371, Gly372, Arg250, Lys327
and His376 in human, respectively; Fig. 5). When fragment molecules
such as FOL680 (PDB entry 3gqt) bind, the main chain rotates to
move all three backbone carbonyls out of position for hydrogen
bonding, partially replacing them with the catalytic glutamyl
carboxylate group (Figs. 5 and 6). The shift from carbonyl to side-
chain carboxylate hydrogen bonding correlates with a backbone shift
that constricts the FAD-binding site and places a His ring near the
binding site for the adenosine of FAD (Fig. 5). Thus, the binding of
small metabolite-like ligands induces a conformation in apo crystals
of BpGCDH that partially ﬁlls the FAD-binding site with protein
residues.
4. Conclusions
We have determined the ﬁrst structure of an intact GCDH holo-
enzyme without FAD or any small molecules present in either the
substrate- or cofactor-binding pockets. Although highly homologous
in structure and sequence, the apo structure of GCDH from
B. pseudomallei revealed a loss of secondary structure and increased
regions of disorder when compared with the previously determined
human GCDH ternary complex. This observation, together with the
relatively high number of crystals that were perturbed or destroyed
during fragment soaking, suggests reduced stability of the BpGCDH
crystal system, most likely owing to the absence of FAD. We have also
discovered novel small-molecule GCDH binders through crystallo-
graphic fragment screening and determined structures for four
BpGCDH fragment-bound complexes. Structural deviations from the
apo state brought about by binding small-molecule fragments reveal
ﬂexibility across certain active-site residues and appear to induce
conformations which move several protein residues into the FAD-
binding pocket.
Some of the mutations associated with glutaric acidemia 1 appear
in the C-terminal region of human GCDH and have been shown to
destabilize FAD binding in vitro, leading to a loss in activity (West-
over et al., 2003). Previous structural and enzymatic studies of GCDH
have repeatedly demonstrated FAD to be a tightly bound cofactor for
this enzyme. Human GCDH recombinantly expressed and puriﬁed in
another laboratory by methods similar to those used here revealed
FAD bound in the crystal structure, although FAD had not been
explicitly added at any stage (Dwyer et al., 2000; Goodman et al.,
1995; Fu et al., 2004). Biochemical efforts to remove FAD from
Pseudomonas ﬂuorescens GCDH in another laboratory required
multiple acid–ammonium precipitation steps, generating a very
unstable protein which lost all activity if FAD was not added back
within minutes (Gomes et al., 1981). Despite high sequence identity
to both proteins (66% to human and 85% to P. ﬂuorescens), GCDH
from B. pseudomallei can be easily separated from FAD through
standard protein-puriﬁcation methods, resulting in an apo protein
that is stable enough for crystallization and X-ray diffraction studies.
This result is consistent with weaker FAD binding to BpGCDH
compared with the human or P. ﬂuorescens enzymes and suggests
that GCDH from B. pseudomallei might provide structural clues
about the behavior of deﬁcient GCDH proteins with reduced co-
factor afﬁnity.
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